Literature DB >> 8212670

Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism.

L Barbolla1, C Paniagua, J Outeiriño, E Prieto, J Sánchez Fayos.   

Abstract

Auto-immune haemolytic anaemia (AIHA) has been found in a case of alpha-interferon treatment. Serum antibody and eluate were positive in the absence of the drug. Although the patient recovered after the treatment was stopped, DAGT remained positive for at least 8 months. The mechanism proposed to explain why this drug induced AIHA is similar to that proposed for alpha-methyl-dopa. Drugs could alter the red cell membrane and impair the immune system. Such changes have been observed with alpha-interferon and were related with increased autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212670     DOI: 10.1111/j.1423-0410.1993.tb02135.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C.

Authors:  A Landau; L Castera; C Buffet; G Tertian; G Tchernia
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

Review 2.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection.

Authors:  Elizabeth Y Chiao; Eric A Engels; Jennifer R Kramer; Kenneth Pietz; Louise Henderson; Thomas P Giordano; Ola Landgren
Journal:  Arch Intern Med       Date:  2009-02-23

4.  Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature.

Authors:  Robert J Basseri; Michael T Schmidt; Benjamin Basseri
Journal:  Clin J Gastroenterol       Date:  2010-08-06

Review 5.  Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia.

Authors:  Tahseen Hamamyh; Mohamed A Yassin
Journal:  Pharmacology       Date:  2020-06-02       Impact factor: 2.547

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.